Introduction
Epicardial adipose tissue is hormonally active tissue that releases adipokines and fatty acids [1, 2] and may be important in HIV patients as it shares an embryonic origin with visceral fat [3] . In non-HIV populations, prior studies have shown associations between pericardial or epicardial fat and visceral adipose tissue (VAT) [4, 5] , insulin resistance [6] , the metabolic syndrome [4, 7] and coronary calcifications [7, 8] . Although prior studies have investigated epicardial fat thickness by echocardiography in HIV-infected patients [9, 10] , no studies have compared epicardial fat volume by computed tomography (CT) in HIV and non-HIV groups. In this study, we investigate epicardial fat volume in HIV and non-HIV patients with similar cardiovascular risk factors and body composition indices to determine whether epicardial fat accumulation occurs and the relationship of epicardial fat to metabolic abnormalities, including glucose parameters, in this population.
Methods Design
In a prospectively recruited cohort of HIV patients and HIV-negative controls [11] , we measured epicardial fat volume by multidetector CT (MDCT) and now present novel data comparing epicardial fat volume between the two groups, assessing the relationship of epicardial fat volume with body composition and metabolic parameters.
Participants
Participants were recruited based on absence of known heart disease and cardiac symptoms with a goal to recruiting two groups with similar cardiovascular risk factors. Participants were not recruited based on anthropometric or body composition parameters [11] .
Assessments
Epicardial fat volume measurements were performed by a single experienced reader using a dedicated semiautomatic program (Siemens Medical Solutions Forchheim, Germany) and similar methodology as previously described [12] . A region of interest was traced on the boundaries of the pericardial layers in every 10 mm with interpolation between the superior and inferior boundary. The top limit of the pericardium fat was the middle of the right pulmonary artery and the lower limit was the apex of the pericardial sac. Fat tissue was defined by voxels with Hounsfield unit (HU) between À30 HU to À190 HU [12] . Body composition and metabolic parameters were determined as previously described [11] . Lipodystrophy was scored as previously reported, rating face, extremities, neck or abdomen as 0-2 for each area [13] .
Statistics

Comparisons between the groups utilized Student's t-test
and Wilcoxon test as appropriate. Univariate and multivariate linear regression were performed using SAS JMP (SAS Institute, Cary, North Carolina, USA).
Results
Seventy-eight HIV-infected men and 32 HIV-seronegative men were studied (Table 1 ). Epicardial fat volume was higher in HIV patients [112 (82-159) cm 3 ] compared to non-HIV-infected controls [85 (58-131) cm 3 ] (P ¼ 0.04). In contrast, VAT, waist circumference, BMI and total body fat were not different between the groups, though the HIV group tended to have less subcutaneous abdominal fat. A minority of participants in each group met criteria for the metabolic syndrome and the proportions did not differ between the groups (Table 1) . Sixteen percent of HIV-infected participants reported having a major feature of lipodystrophy (score of 2 at one or more sites).
Relationship of epicardial fat with body composition and metabolic parameters in HIV patients
Body composition
Epicardial fat was associated with BMI (r ¼ 0.48, P < 0.0001), VAT (r ¼ 0.76, P < 0.0001), subcutaneous adipose tissue (SAT) (r ¼ 0.39, P ¼ 0.002), total fat mass (r ¼ 0.62, P < 0.0001) and lean mass (r ¼ 0.37, P < 0.004). In a model including BMI, VAT, SAT, total fat mass and lean mass, VAT was the only body composition measurement that remained significantly associated with epicardial fat (b ¼ 0.30 cm 3 /cm 2 , P < 0.0001, model r 2 ¼ 0.57). Additional sensitivity analysis adjusting for body composition parameters as well as age, protease inhibitor and nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) use also demonstrated similar results. Among HIV-infected patients without the metabolic syndrome, similar results were seen.
Metabolic parameters
Epicardial fat was positively associated with fasting glucose (r ¼ 0.41, P ¼ 0.001), fasting insulin (r ¼ 0.44, P ¼ 0.0003) and 2-h insulin (r ¼ 0.25, P ¼ 0.04) and negatively associated with adiponectin (r ¼ À0.26, P ¼ 0.04), CD4 (r ¼ 0.28, P ¼ 0.02) and CD8 cells (r ¼ 0.39, P ¼ 0.001), but not with C-reactive protein (CRP) (r ¼ 0.09, P ¼ 0.47), monocyte chemoattractant protein-1 (r ¼ 0.08, P ¼ 0.55) or IL-6 (r ¼ À0.05, P ¼ 0.73). 
AIDS 2010, Vol 24 No 13
Coronary atherosclerosis and ventricular function
No correlation was found between epicardial fat and plaque volume (r ¼ À0.12, P ¼ 0.35), segments with plaque (r ¼ À0.06, P ¼ 0.64) or with calcium score (r ¼ À0.02, P ¼ 0.89). All but three HIV patients had normal left ventricular function assessed by cardiac CT. Median epicardial fat volume was 156.7 (107.0-241.1) cm 3 in the three patients with decreased ventricular function and 110.6 (81.1-158.7) cm 3 in HIV patients with normal cardiac function.
Multivariate modeling in HIV patients
Epicardial fat remained significantly associated with fasting glucose (b ¼ 0.10 cm 3 /mg/dl, P ¼ 0.02) in a model including age, race, BMI, adiponectin, VAT, current protease inhibitor use and current NRTI use. Similar results were seen in modeling with fasting insulin (b ¼ 0.07 cm 3 /mU/ml, P ¼ 0.03). Self-reported nadir CD4 count was available for 58 HIV-infected patients. After controlling for nadir CD4 count, epicardial fat volume remained significantly associated with fasting glucose (b ¼ 0.08 cm 3 /mg/dl, P ¼ 0.005) and insulin (b ¼ 0.09 cm 3 /mU/ml, P ¼ 0.0002).
Relationship of epicardial fat with metabolic parameters in non-HIV-infected patients
Among HIV-negative controls, epicardial fat was associated with age (r ¼ 0.51,
BMI (r ¼ 0.81, P < 0.0001), total fat (r ¼ 0.88, P < 0.0001), SAT (r ¼ 0.78, P < 0.0001) and VAT (r ¼ 0.85, P < 0.0001).
Discussion
The current study demonstrates that epicardial fat volume was significantly higher in HIV patients compared to a well-matched control group that did not differ significantly with respect to other body composition parameters. Among HIV patients, epicardial fat volume correlated most highly with visceral obesity, more so than overall adiposity or other body composition parameters.
In a prior study of HIV patients on highly-active antiretroviral therapy (HAART) with lipodystrophy and the metabolic syndrome, epicardial fat thickness measured by echocardiography correlated with VAT and intima-media thickness [9] . In contrast, patients in our study were not recruited based on the presence of fat redistribution or the metabolic syndrome. Moreover, the majority of patients did not have the metabolic syndrome and the relationships with epicardial fat volume were similar and remained highly significant when analysis was limited to only those without the metabolic syndrome.
In this study, we present novel data among HIV patients demonstrating a moderate but significant relationship between glucose parameters and epicardial fat volume that appears to be independent of other factors known to regulate glucose homeostasis, including VAT. Additional studies are needed to determine whether development of excess epicardial adipose tissue contributes to the insulin resistance in this population and whether reducing epicardial fat should be targeted in this regard.
Our current data demonstrate that CD4 þ and CD8 þ T-lymphocytes are associated with epicardial fat. T-lymphocytes are increased in the adipose tissue of obese humans, potentially playing a role in obesity-related inflammation [14, 15] . Studies are needed to assess whether there is an independent relationship between epicardial fat and immune function in HIV-infected patients.
Our data demonstrate for the first time that epicardial adipose tissue, assessed volumetrically by MDCT, is increased in HIV patients and related to visceral adiposity. Epicardial fat is significantly associated with fasting glucose and insulin in HIV-infected patients, independently of traditional factors affecting glucose homeostasis. Investigation of the mechanisms, clinical significance and potential therapeutic strategies for epicardial fat accumulation in HIV patients is needed.
Funding sources had no role in the design of the study, data analysis or the writing of the article. We report the concentrations of maraviroc in the cerebrospinal fluid (CSF) and plasma of six HIV-1infected patients with both neurological impairment and detectable HIV-1 replication in CSF. One month after starting maraviroc, the viral load in the CSF decreased significantly (P U 0.005). The median (range) maraviroc concentration in plasma was 347 ng/ml (123-2678). Four patients had CSF concentrations above the protein-adjusted inhibitory concentration (IC 90 ) of 0.57 ng/ml (0.06-10.7) with a median of 102 ng/ml (35-173).
The central nervous system (CNS) is one of the main targets of HIV-1 infection [1, 2] . HIV-1-associated encephalitis and AIDS dementia complex are related to viral replication in the CNS [3] [4] [5] . Many antiretroviral drugs are largely unable to cross the blood-brain barrier (BBB), raising concerns that the CNS may be a compartment where HIV-1 can replicate despite optimal combined antiretroviral treatment (cART) [6, 7] . Maraviroc binds specifically to the chemokine CCR5 HIV-1 coreceptor on the surface of CD4 cells [8] . Most HIV-1 strains isolated from the CSF of individuals with HIV-1 encephalitis are viruses that use CCR5 [9, 10] ; maraviroc may therefore be useful in these patients.
We evaluated the efficacy of maraviroc as part of a cART for antiretroviral-naive and antiretroviral-experienced HIV-1 patients with CNS disease. We also determined steady-state concentrations of maraviroc in CSF and plasma.
We identified patients with neurological impairment who had started maraviroc as part of a cART. The protein concentration and cell count in CSF and HIV-1 RNA load in plasma and CSF were analyzed before the introduction or modification of cART and after 1 month of treatment. Drug concentrations in plasma and CSF were also determined after 1 month. Trough antiretroviral drug concentrations in plasma and CSF were determined at steady state using the Ultra Performance Liquid Chromatograph mass tandem spectrometer (UPLC/MS/ MS method, Acquity UPLC-Acquity TQD) (Waters Corporation, Milford, Massachussets, USA) after sample pretreatment. HIV-1 RNA in plasma and CSF was quantified using Amplicor (1.5 HIV Monitor Kit; Roche, Branchburg, New Jersey, USA) with a detection limit of 50 copies/ml in plasma and 200 copies/ml in CSF. Blood CD4 þ cell count was determined by Facscount (Immunochemistry Systems, Becton Dickinson, Miami, Florida, USA). Nonparametric tests were used for group descriptive analysis and for maraviroc concentrations.
Results are presented as median (range) values.
The characteristics of the six patients are presented in Table 1 . The median age was 44 years (30-55) and the nadir CD4 cell count was 59 Â 10 6 cells/ml . At the time of the neurological episode, two patients (patients 1 and 3) were antiretroviral naive and had a plasma viral load of 4.8 log 10 copies/ml and four (patients 2, 4, 5 and 6) were on cART with a plasma viral load of 2.4 log 10 copies/ml (1.6-4.6). At baseline, all but one (patient 1) presented hypercellular CSF (CSF cells 32 Â 10 6 cells, 1-320) and the CSF protein concentration was high in five of the patients (0.85 g/l, 0.44-2.00). All patients had a detectable HIV-1 viral load in the CSF (3.6 log 10 copies/ml, 2.9-4.8).
A CCR5-tropic strain was isolated from five patients and a chemokine (C-X-C motif) receptor 4 (CXCR4)-tropic strain from one (patient 3). Coreceptor tropism of CSF and plasma isolates was concordant in four patients with CCR5-tropic strains and in the patient with a CXCR4tropic strain. After the diagnosis of CNS disease, maraviroc was added to the cART boosted with ritonavir (Table 1) . After 1 month, the clinical status of all but one patient (patient 3) improved and both plasma and CSF viral loads in all six patients decreased significantly (P ¼ 0.03 and P ¼ 0.005). The median plasma concentration (12 AE 2 h) of maraviroc was 347 ng/ml (123-2678). In two patients, maraviroc CSF concentrations were below the detection threshold of 10 ng/ml (patients 2 and 4), although the plasma concentrations of maraviroc were 269 and 123 ng/ml, respectively. In the other four patients, the median trough maraviroc concentration was 102 ng/ml (35-173), which is above the protein-adjusted IC 90 (drug concentration needed to inhibit 90% of viral replication) of 0.57 ng/ml (0.06-10.7). The median CSF/plasma ratio was 0.29, which is close to the free fraction of protein binding for maraviroc. CSF concentrations of maraviroc did not correlate with maraviroc plasma concentrations, CSF protein concentrations or CSF white blood cell counts.
We report the effects of maraviroc-containing cART regimens on CSF viral load in six patients with neurological symptoms. In all cases, both the HIV-1 viral load and cell count in the CSF were significantly reduced within 1 month of treatment.
Our study is an observational study and we cannot rule out the possibility that modification of the cART would have been sufficient for better control of viral replication in the CSF. All patients were receiving treatment with antiretroviral drugs other than maraviroc, including abacavir, lamivudine and zidovudine, which are known to cross the BBB [11, 12] .
Maraviroc was detected in the CSF from four of the six patients, with concentrations exceeding the IC 90 value. This is consistent with maraviroc contributing to the inhibition of HIV-1 replication in the CNS. Previous studies have shown elevated maraviroc concentrations in the female genital tract and the biochemical properties of maraviroc, particularly, its low molecular weight and free fraction of protein binding (24%), makes this molecule a good candidate for being able to penetrate HIV-1 sanctuary sites [13, 14] .
In some patients, we found no relationship between maraviroc concentrations in the plasma and CSF; a higher dose of ritonavir-boosted maraviroc may be necessary to ensure higher plasma concentrations and subsequent crossing the BBB into the CSF.
Interestingly, we found higher maraviroc CSF concentrations than reported in a recent study by Yilmaz et al. [15] . One possible reason for this discrepancy is boosting with ritonavir, which inhibits the P-glycoprotein efflux pump (P-gp) [16] . The selective inhibition of P-gp in the BBB may facilitate the entry of antiretroviral drugs like maraviroc [17] . Moreover, Yilmaz et al. [15] describe maraviroc concentrations in asymptomatic patients, whereas we studied patients suffering neurological impairments with high CSF cell counts and protein concentrations. BBB inflammation may facilitate entry of antiretroviral drugs into the CSF and result in higher concentrations in this compartment. Indeed, the permeability of the BBB in our patients resulted in a median CSF/plasma ratio of 0.29, which is near to the free fraction of protein binding for maraviroc.
In conclusion, maraviroc-containing cART significantly reduced the HIV-1 load in both plasma and CSF. Maraviroc concentrations in the CSF and plasma were within the therapeutic range and correlated in four out of six patients. These results indicate that maraviroc should be considered in cARTregimens for advanced stage AIDS patients suffering neurological disease. This study's purpose was to determine whether asthma medication use in HIV positive children is associated with human leukocyte antigen (HLA) alleles. We reviewed HLA and medication data collected during the Women and Infants Transmission Study for 124 HIV positive children and their mothers. Analysis revealed that HLA-A68 (P U 0.006) was independent and predictive for time to first asthma medication use. There was a preventive association of Cw6 (P U 0.008) with asthma time. Highly active antiretroviral therapy (HAART) was also associated with time to first asthma medication use (P U 0.05). HLA alleles may modulate risk of developing a need for asthma medications and seem to function independently of the actions of HAART therapy.
Evidence from adult and pediatric studies suggests that CD4 þ T cells have a critical role in the development of asthma in children with HIV infection [1] [2] [3] [4] [5] . There have been numerous studies of human leukocyte antigen (HLA) genes as predictors for childhood atopy and asthma, including the major histocompatibility complex (MHC) class II restricted T cells. Several studies have found associations between HLA genes and asthma and allergy susceptibility (e.g. Juhn et al. [6] ).
To examine the possibility of HLA associations with asthma in HIV infection, investigators of the Women and Infants Transmission Study (WITS), a large multicenter pediatric cohort (n ¼ 2471) with documented HIV-1 inutero exposure [7] , reviewed the HIV positive (HIVinfected, n ¼ 193) cohort for the use of asthma medication [5] and performed HLA typing. The results of that investigation are reported herein.
A subset of 124 HIV positive WITS patients with available data/specimens underwent HLA typing by sequence-specific PCR performed to the two digit allelic level. DNA isolation and sequence-based HLA typing was performed using the method as described by Winchester et al. [8] and Johnston-Dow et al. [9] . Haplotypes were determined by direct comparison of the typing of the mother and her infant. Maternal and paternal haplotypes were identified.
Asthma was defined in terms of asthma medication use rather than by parental report of wheezing, reactive airways disease, or asthma [10, 11] . The time to first asthma medication was defined as asthma time.
A multistaged approach was used to identify the final association models relating risk factors to the asthma medication use. The population baseline characteristics were compared by asthma medication use (yes/no) as determined during the WITS follow-up. Differences in continuous variables were assessed by using t-tests, and differences in categorical variables were assessed by using the Fisher's exact test.
Univariate analyses were first performed to assess the associations between asthma time and HLA alleles using the log-rank statistic. All the covariates that were significant at P ¼ 0.10 level were further evaluated in multivariate analyses using the COX model [12] . The final multivariate model was built using a backward selection technique that forced the highly active antiretroviral therapy (HAART) variable to remain in the model. To reduce the number of spurious associations due to the large number of tests being performed in this study, a significance level of P ¼ 0.01 for statistical inference was used as the criterion for keeping a variable in a multivariate model analysis. We evaluated every subject from their birth to the end of WITS followup. Nonevent-related interval censoring occurred when a subject was lost to follow-up. The Breslow method for handling event/censoring ties was used to establish each contribution to the likelihood ratio. In the COX proportional hazard model analyses, data were arranged using counting process style of input to incorporate timedependent variables [12, 13] . The COX model's proportionality assumption was checked by plotting log negative log survival density functions for the final model. The proportionality assumption was not violated for the two HLA alleles that remained in the final model (HLA-A68 and HLA-Cw6).
Reported P-values from COX proportional hazard models were calculated using likelihood ratio test (comparing the full and reduced likelihoods), as number of events in a risk factor category was small (i.e. HLA Cw6).
HLA typing was performed on 124 infants in the WITS study. Sex, race/ethnicity, and ability to pay for medical costs (socioeconomic status) did not differ by asthma medication status. The study population was predominantly of minority race and ethnic groups and was composed of inner city dwellers [7] . The study cohort is ethnically diverse, with 52 African-Americans, 43 Hispanics, 21 Caucasians and eight infants in other ethnic categories. Children with a history of asthma medication use were more likely to have been treated with HAART therapy.
Analysis of MHC class I A, B, and C and class II DRB1
and DRB345 alleles is shown in the Table 1 (only HLA surviving alleles associated with asthma are shown). There were six HLA class I alleles that were either associated with or protective against asthma medication use at the P ¼ 0.10 level in the preliminary association analyses (HLA-A68, HLA-B13, HLA-B39, HLA-B55, HLA-Cw4, and HLA-Cw6; Table 1 ). Thirty-three percent of individuals possessing at least one HLA-A68 allele had a history of asthma medication use vs. 9% of individuals without the allele. Rates of comparison for the other alleles were 50 vs. 13% for HLA-B13, 50 vs. 13% for HLA-B39, 100 vs. 13% for HLA-B55, 23 vs. 12% for HLA-Cw4. The HLA-Cw6 allele was associated with lack of asthma medication use. The rates of comparisons were 0 vs. 18% for HLA-Cw6.
Candidate alleles, including the long-term nonprogression alleles HLA-B27 and B57, and HAART medication use were subjected to multivariate analysis using the Cox model to examine the independent associations of HLA allele and HAART treatment with asthma time (Table 1) . After a backward selection and forcing HAART medication use to remain in the final model because earlier results [3] [4] [5] have indicated that this variable is related to immunoreconstitution, the final model contained variables for HLA-A68 (P ¼ 0.006, increased risk for asthma medication use), HLA-Cw6 (P ¼ 0.008, decreased risk) and HAART therapy (P ¼ 0.05, increased risk) ( Table 1) . HLA-B27 and HLA-B57, along with HLA-B13, HLA-B39, HLA-B55 and HLA-Cw4, were all excluded from the final model with a significance level to stay at 0.01. Also, we tested the interaction of HAART use with HLA-A68 and HLA-Cw6 but these tests did not meet the statistical significance criterion to remain in the final model.
In summary, stimulated by the unexpected discovery of a CD4 þ T cell dependent increased incidence and prevalence of asthma in HIV positive children treated with HAART, we sought an alternate explanation for this observation. We performed HLA analysis of children with and without asthma in the same cohort WITS study. Our discovery was that inheritance of certain HLA class I alleles, A68 and Cw6, are independent predictors of asthma medication use in HIV positive children; A68 predicts increased incidence and Cw6 predicts decreased incidence, and both are independent of the increased incidence of asthma attributable to HAART itself. Thus, immunoreconstitution of a suppressed immune system in HIV infection may produce immunological events that trigger bronchial hyperresponsiveness and autoimmune disorders, particularly in those individuals with an underlying genetic predisposition. The relatively small number of patients in this study makes us interpret our results with caution. Longer term follow-up may have yielded more patients with asthma.
